On the 4th, Tanvex BioPharma (泰福-KY) announced that its board of directors has appointed Stephen Lam as CEO, effective August 5. With over 35 years of global operational experience in large-molecule biologics, Lam will oversee Tanvex's daily operations across Taiwan and the U.S., including its global CDMO (Contract Development and Manufacturing Organization) business development and the mass production and market launch of its biosimilars. His leadership marks a significant step in guiding Tanvex toward becoming a key player in the international CDMO landscape.
Read more
